 | Up a level |
van der Maas, Niek G; Versluis, Jurjen; Nasserinejad, Kazem; van Rosmalen, Joost; Pabst, Thomas; Maertens, Johan; Breems, Dimitri; Manz, Markus; Cloos, Jacqueline; Ossenkoppele, Gert J; Floisand, Yngvar; Gradowska, Patrycja; Löwenberg, Bob; Huls, Gerwin; Postmus, Douwe; Pignatti, Francesco; Cornelissen, Jan J (2024). Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial. Blood cancer journal, 14(56) Nature Publishing Group 10.1038/s41408-024-01037-3
Tettero, Jesse M; Buisman, Yara; Ngai, Lok Lam; Bachas, Costa; Gjertsen, Bjorn T; Kelder, Angèle; van de Loosdrecht, Arjan A; Manz, Markus G; Pabst, Thomas; Scholten, Willemijn; Ossenkoppele, Gert J; Cloos, Jacqueline; de Leeuw, David C (2023). Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. HemaSphere, 7(12), e981. Wolters Kluwer Health 10.1097/HS9.0000000000000981
Tettero, Jesse M; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J W M; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J M; Löwenberg, Bob; Ossenkoppele, Gert J; Cloos, Jacqueline (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica - the hematology journal, 108(10), pp. 2794-2798. Ferrata-Storti Foundation 10.3324/haematol.2022.282639
Hilberink, Jacobien R; van Zeventer, Isabelle A; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2023). Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. Blood cancer journal, 13(1), p. 93. Springer Nature 10.1038/s41408-023-00850-6
Ngai, Lok Lam; Hanekamp, Diana; Janssen, Fleur; Carbaat-Ham, Jannemieke; Hofland, Maaike A M; Fayed, Mona M H E; Kelder, Angèle; Oudshoorn-van Marsbergen, Laura; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Griskevicius, Laimonas; Juliusson, Gunnar; van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; ... (2023). Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood, 141(21), pp. 2657-2661. American Society of Hematology 10.1182/blood.2022019160
Grob, Tim; Al Hinai, Adil S A; Sanders, Mathijs A; Kavelaars, François G; Rijken, Melissa; Gradowska, Patrycja L; Biemond, Bart J; Breems, Dimitri A; Maertens, Johan; van Marwijk Kooy, Marinus; Pabst, Thomas; de Weerdt, Okke; Ossenkoppele, Gert J; van de Loosdrecht, Arjan A; Huls, Gerwin A; Cornelissen, Jan J; Beverloo, H Berna; Löwenberg, Bob; Jongen-Lavrencic, Mojca and Valk, Peter J M (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 139(15), pp. 2347-2354. American Society of Hematology 10.1182/blood.2021014472
Bakunina, Katerina; Putter, Hein; Versluis, Jurjen; Koster, Eva A S; van der Holt, Bronno; Manz, Markus G; Breems, Dimitri A; Gjertsen, Bjorn T; Cloos, Jacqueline; Valk, Peter J M; Passweg, Jakob; Pabst, Thomas; Ossenkoppele, Gert J; Löwenberg, Bob; Cornelissen, Jan J; de Wreede, Liesbeth C (2022). The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. Cancer medicine, 11(3), pp. 630-640. Wiley 10.1002/cam4.4392
Tettero, Jesse M; Al-Badri, Waleed K W; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; van Elssen, Catharina H M J; Fischer, Thomas; Gjertsen, Bjorn T; van Gorkom, Gwendolyn N Y; Gradowska, Patrycja; Greuter, Marjolein J E; Griskevicius, Laimonas; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Löwenberg, Bob; Ossenkoppele, Gert J; ... (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Frontiers in oncology, 12, p. 999822. Frontiers Research Foundation 10.3389/fonc.2022.999822
Brune, Magdalena M; Stüssi, Georg; Lundberg, Pontus; Vela, Visar; Heim, Dominik; Manz, Markus G; Haralambieva, Eugenia; Pabst, Thomas; Banz, Yara; Bargetzi, Mario; Grobholz, Rainer; Fehr, Martin; Cogliatti, Sergio; Ossenkoppele, Gert J; Löwenberg, Bob; Rudolf, Christina Biaggi; Li, Qiyu; Passweg, Jakob; Mazzuchelli, Luca; Medinger, Michael; ... (2021). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Annals of hematology, 100(5), pp. 1169-1179. Springer-Verlag 10.1007/s00277-021-04467-2
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; Gradowska, Patrycja; Biemond, Bart J; Spertini, Olivier; Vellenga, Edo; Griskevicius, Laimonas; Tick, Lidwine W; Jongen-Lavrencic, Mojca; van Marwijk Kooy, Marinus; Vekemans, Marie-Christiane; van der Velden, Walter J F M; Beverloo, Berna; Michaux, Lucienne; Graux, Carlos; Deeren, Dries; de Weerdt, Okke; van Esser, Joost W J; Bargetzi, Mario; ... (2021). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood advances, 5(4), pp. 1110-1121. American Society of Hematology 10.1182/bloodadvances.2020003855
Huls, Gerwin; Chitu, Dana A; Pabst, Thomas; Klein, Saskia K; Stussi, Georg; Griskevicius, Laimonas; Valk, Peter J M; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Breems, Dimitri; van Lammeren-Venema, Danielle; van Zeventer, Isabelle; Boersma, Rinske; Jongen-Lavrencic, Mojca; Fehr, Martin; Hoogendoorn, Mels; Manz, Markus G; Söhne, Maaike; van Marwijk Kooy, Rien; Deeren, Dries; ... (2020). Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood advances, 4(18), pp. 4267-4277. American Society of Hematology 10.1182/bloodadvances.2020002846
de Jong, Greta; Janssen, Jeroen J W M; Biemond, Bart J; Zeerleder, Sacha S.; Ossenkoppele, Gert J; Visser, Otto; Nur, Erfan; Meijer, Ellen; Hazenberg, Mette D (2019). Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies. European journal of haematology, 103(5), pp. 491-499. Wiley-Blackwell 10.1111/ejh.13315
Zeijlemaker, Wendelien; Grob, Tim; Meijer, Rosa; Hanekamp, Diana; Kelder, Angèle; Carbaat-Ham, Jannemieke C; Oussoren-Brockhoff, Yvonne J M; Snel, Alexander N; Veldhuizen, Dennis; Scholten, Willemijn J; Maertens, Johan; Breems, Dimitri A; Pabst Müller, Thomas Niklaus; Manz, Markus G; van der Velden, Vincent H J; Slomp, Jennichjen; Preijers, Frank; Cloos, Jacqueline; van de Loosdrecht, Arjan A; Löwenberg, Bob; ... (2019). CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 33(5), pp. 1102-1112. Nature Publishing Group 10.1038/s41375-018-0326-3
Jongen-Lavrencic, Mojca; Grob, Tim; Hanekamp, Diana; Kavelaars, François G; Al Hinai, Adil; Zeilemaker, Annelieke; Erpelinck-Verschueren, Claudia A J; Gradowska, Patrycja L; Meijer, Rosa; Cloos, Jacqueline; Biemond, Bart J; Graux, Carlos; van Marwijk Kooy, Marinus; Manz, Markus G; Pabst Müller, Thomas Niklaus; Passweg, Jakob R; Havelange, Violaine; Ossenkoppele, Gert J; Sanders, Mathijs A; Schuurhuis, Gerrit J; ... (2018). Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England journal of medicine NEJM, 378(13), pp. 1189-1199. Massachusetts Medical Society MMS 10.1056/NEJMoa1716863
Löwenberg, Bob; Pabst, Thomas; Maertens, Johan; van Norden, Yvette; Biemond, Bart J; Schouten, Harry C; Spertini, Olivier; Vellenga, Edo; Graux, Carlos; Havelange, Violaine; de Greef, Georgine E; de Weerdt, Okke; Legdeur, Marie-Cecile J C; Kuball, Juergen; Kooy, Marinus van Marwijk; Gjertsen, Bjorn T; Jongen-Lavrencic, Mojca; van de Loosdrecht, Arjan A; van Lammeren-Venema, Daniëlle; Hodossy, Beata; ... (2017). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 129(12), pp. 1636-1645. American Society of Hematology 10.1182/blood-2016-10-740613
Walter, Roland B; Othus, Megan; Löwenberg, Bob; Ossenkoppele, Gert J; Petersdorf, Stephen H; Pabst, Thomas; Vekemans, Marie-Christiane; Appelbaum, Frederick R; Erba, Harry P; Estey, Elihu H (2015). Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica - the hematology journal, 100(10), e409-e411. Ferrata-Storti Foundation 10.3324/haematol.2015.130013
Terwijn, Monique; Zeijlemaker, Wendelien; Kelder, Angèle; Rutten, Arjo P; Snel, Alexander N; Scholten, Willemijn J; Pabst, Thomas; Verhoef, Gregor; Löwenberg, Bob; Zweegman, Sonja; Ossenkoppele, Gert J; Schuurhuis, Gerrit J (2014). Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE, 9(9), e107587. Public Library of Science 10.1371/journal.pone.0107587
Gröschel, Stefan; Schlenk, Richard F; Engelmann, Jan; Rockova, Veronika; Teleanu, Veronica; Kühn, Michael W M; Eiwen, Karina; Erpelinck, Claudia; Havermans, Marije; Lübbert, Michael; Germing, Ulrich; Schmidt-Wolf, Ingo G H; Beverloo, H Berna; Schuurhuis, Gerrit J; Ossenkoppele, Gert J; Schlegelberger, Brigitte; Verdonck, Leo F; Vellenga, Edo; Verhoef, Gregor; Vandenberghe, Peter; ... (2013). Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of clinical oncology, 31(1), pp. 95-103. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.41.5505
Ossenkoppele, Gert J; Stussi, Georg; Maertens, Johan; van Montfort, Kees; Biemond, Bart J; Breems, Dimitri; Ferrant, August; Graux, Carlos; de Greef, Georgine E; Halkes, C J M; Hoogendoorn, Mels; Hollestein, Rene M; Jongen-Lavrencic, Mojca; Levin, Mark D; van de Loosdrecht, Arjan A; van Marwijk Kooij, Marinus; van Norden, Yvette; Pabst, Thomas; Schouten, Harry C; Vellenga, Edo; ... (2012). Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood, 120(24), pp. 4706-11. Washington, D.C.: American Society of Hematology 10.1182/blood-2012-04-420596
Cornelissen, Jan J; Breems, Dimitri; van Putten, Wim L J; Gratwohl, Alois A; Passweg, Jakob R; Pabst, Thomas; Maertens, Johan; Beverloo, H Berna; van Marwijk Kooy, Marinus; Wijermans, Pierre W; Biemond, Bart J; Vellenga, Edo; Verdonck, Leo F; Ossenkoppele, Gert J; Löwenberg, Bob (2012). Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. Journal of clinical oncology, 30(17), pp. 2140-6. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.39.6499
Löwenberg, Bob; Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Biemond, Bart J; Gratwohl, Alois; de Greef, Georgine E; Verdonck, Leo F; Schaafsma, Martijn R; Gregor, Michael; Theobald, Matthias; Schanz, Urs; Maertens, Johan; Ossenkoppele, Gert J (2011). Cytarabine dose for acute myeloid leukemia. New England journal of medicine NEJM, 364(11), pp. 1027-36. Waltham, Mass.: Massachusetts Medical Society MMS
Vellenga, Edo; van Putten, Wim; Ossenkoppele, Gert J; Verdonck, Leo F; Theobald, Matthias; Cornelissen, Jan J; Huijgens, Peter C; Maertens, Johan; Gratwohl, Alois; Schaafsma, Ron; Schanz, Urs; Graux, Carlos; Schouten, Harry C; Ferrant, Augustin; Bargetzi, Mario; Fey, Martin F; Löwenberg, Bob; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), ; Swiss Group for Clinical Cancer Research Collaborative Group (SA, (2011). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 118(23), pp. 6037-42. Washington, D.C.: American Society of Hematology 10.1182/blood-2011-07-370247
Löwenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C; Verdonck, Leo F; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, Ron; Verhoef, Gregor; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert J; ... (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), pp. 2586-91. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-10-246470
Löwenberg, Bob; Ossenkoppele, Gert J; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; van Marwijk Kooy, Marinus; Verdonck, Leo F; Beck, Joachim; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Verhoef, Gregor (2009). High-dose daunorubicin in older patients with acute myeloid leukemia. New England journal of medicine NEJM, 361(13), pp. 1235-48. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa0901409
van den Heuvel-Eibrink, Marry M; van der Holt, Bronno; Burnett, Alan K; Knauf, Wolfgang U; Fey, Martin F; Verhoef, Gregor E G; Vellenga, Edo; Ossenkoppele, Gert J; Löwenberg, Bob; Sonneveld, Pieter (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of hematology, 86(5), pp. 329-37. Berlin: Springer 10.1007/s00277-007-0269-7
